中华内分泌外科杂志
中華內分泌外科雜誌
중화내분비외과잡지
CHINESE JOURNAL OF ENDOCRINE SURGERY
2011年
1期
49-51
,共3页
利拉鲁肽%成纤维细胞生长因子-21%2型糖尿病
利拉魯肽%成纖維細胞生長因子-21%2型糖尿病
리랍로태%성섬유세포생장인자-21%2형당뇨병
Liraglutide%Fibroblast growth factor-21%Type 2 diabetes mellitus
目的 观察利拉鲁肽(Liraglutide)对2型糖尿病(T2DM)患者血浆成纤维细胞生长因子-21(FGF-21)水平的影响.方法 采用酶联免疫法测定T2DM患者及正常人血浆FGF-21水平,分析血浆FGF-21水平与BMI、WHR、稳态模型胰岛素抵抗指数(HOMA-IR)、稳态模型胰岛β细胞分泌指数(HO-MA-IS)、游离脂肪酸(FFA)等的关系,Liraglutide治疗前后T2DM患者血浆FGF-21水平的变化.结果 T2DM患者血浆FGF-21水平明显高于正常对照(1.81±0.32 vs 1.32±0.09,P＜0.01).T2DM患者经Liraglutide治疗后WHR、BMI、FBG、2hPBG、HbA1c和FFA均显著降低(P＜0.05或P＜0.01),而HO-MA-IS则显著增高(P＜0.01),但FGF-21变化无明显差异(P＞0.05).结论 Liraglutide和FGF-21在胰岛素抵抗的发生和发展中可能具有不同的作用机制.
目的 觀察利拉魯肽(Liraglutide)對2型糖尿病(T2DM)患者血漿成纖維細胞生長因子-21(FGF-21)水平的影響.方法 採用酶聯免疫法測定T2DM患者及正常人血漿FGF-21水平,分析血漿FGF-21水平與BMI、WHR、穩態模型胰島素牴抗指數(HOMA-IR)、穩態模型胰島β細胞分泌指數(HO-MA-IS)、遊離脂肪痠(FFA)等的關繫,Liraglutide治療前後T2DM患者血漿FGF-21水平的變化.結果 T2DM患者血漿FGF-21水平明顯高于正常對照(1.81±0.32 vs 1.32±0.09,P＜0.01).T2DM患者經Liraglutide治療後WHR、BMI、FBG、2hPBG、HbA1c和FFA均顯著降低(P＜0.05或P＜0.01),而HO-MA-IS則顯著增高(P＜0.01),但FGF-21變化無明顯差異(P＞0.05).結論 Liraglutide和FGF-21在胰島素牴抗的髮生和髮展中可能具有不同的作用機製.
목적 관찰리랍로태(Liraglutide)대2형당뇨병(T2DM)환자혈장성섬유세포생장인자-21(FGF-21)수평적영향.방법 채용매련면역법측정T2DM환자급정상인혈장FGF-21수평,분석혈장FGF-21수평여BMI、WHR、은태모형이도소저항지수(HOMA-IR)、은태모형이도β세포분비지수(HO-MA-IS)、유리지방산(FFA)등적관계,Liraglutide치료전후T2DM환자혈장FGF-21수평적변화.결과 T2DM환자혈장FGF-21수평명현고우정상대조(1.81±0.32 vs 1.32±0.09,P＜0.01).T2DM환자경Liraglutide치료후WHR、BMI、FBG、2hPBG、HbA1c화FFA균현저강저(P＜0.05혹P＜0.01),이HO-MA-IS칙현저증고(P＜0.01),단FGF-21변화무명현차이(P＞0.05).결론 Liraglutide화FGF-21재이도소저항적발생화발전중가능구유불동적작용궤제.
Objective To investigate the effects of Liraglutide on plasma FGF-21 level in patients with type 2 diabetes mellitus (T2DM). Methods Enzyme linked immunosorbent assay (ELISA) was used to measure plasma FGF-21 level in patients with T2DM and normal controls (NGT). Relationship between plasma FGF-21level and BMI, WHR, HOMA-IR, HOMA-IS, FFA was analyzed. After Liraglutide treatment, plasma FGF-21level was observed in patients with T2DM. Results Fasting plasma FGF-21 level was higher in T2DM patients than that in normal control group ( 1.81 ±0.32 vs. 1.32 ±0.09 μg/L, P ＜0.01 ). After Liraglutide treatment, WHR, BMI, FPG, 2hPBG, HbA1c and FFA in T2DM patients significantly decreased ( P ＜0.05 or P ＜0. 01 ),HOMA-IS remarkably increased (P ＜ 0. 01 ), and FGF-21 had no change. Conclusion Liraglutide and FGF-21may have different roles in insulin resistance.
